Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2

Tia A. Tummino(University of California, San Francisco), Brian K. Shoichet(University of California, San Francisco), Michael Schotsaert(Icahn School of Medicine at Mount Sinai), Briana L McGovern(Icahn School of Medicine at Mount Sinai), Jiankun Lyu(University of California, San Francisco), Blandine Monel(Centre National de la Recherche Scientifique), François Pognan(Novartis (Switzerland)), Francesca Moretti(Novartis (Switzerland)), Nevan J. Krogan(QB3), Henry O’Donnell(University of California, San Francisco), Raveen Rathnasinghe(Seqirus (United States)), Veronica V. Rezelj(Human Vaccines Project Europe), Kris M. White(Icahn School of Medicine at Mount Sinai), Olivier Schwartz(Centre National de la Recherche Scientifique), Romel Rosales(Icahn School of Medicine at Mount Sinai), Audrey Fischer(Novartis (Switzerland)), László Urbán(University of Matanzas), Thomas Vallet(Centre National de la Recherche Scientifique), Sonia Jangra(Icahn School of Medicine at Mount Sinai), Jean-René Galarneau(Novartis (Switzerland)), Assaf Alon(Harvard University), Andrew C. Kruse(Harvard University), Kevan M. Shokat(Howard Hughes Medical Institute), Marco Vignuzzi(Agency for Science, Technology and Research), Benoit Fischer(Institut de génétique et de biologie moléculaire et cellulaire), Ziyang Zhang(University of California, Berkeley), Matthew J. O’Meara(University of Michigan), Heiko S. Schadt(Novartis (Switzerland)), Adolfo García‐Sastre(Office of Infectious Diseases)
Science
June 22, 2021
Cited by 223


Related Papers